DURECT (NASDAQ:DRRX) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a research note issued to investors on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Stock Down 5.0 %

DURECT stock opened at $0.77 on Thursday. The firm has a market cap of $23.75 million, a P/E ratio of -1.25 and a beta of 0.94. The business has a fifty day moving average of $0.85 and a two-hundred day moving average of $1.19. DURECT has a twelve month low of $0.68 and a twelve month high of $1.88.

Institutional Investors Weigh In On DURECT

A hedge fund recently raised its stake in DURECT stock. Geode Capital Management LLC grew its holdings in shares of DURECT Co. (NASDAQ:DRRX) by 4.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 319,905 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,658 shares during the period. Geode Capital Management LLC owned approximately 1.03% of DURECT worth $429,000 at the end of the most recent quarter. Institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.